PFE Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of 19%. Pfizer Inc.'s return on equity of 10.84% beat Biogen, Inc.'s return on equity of 9.36%.

Pfizer Inc. has a consensus price target of $28.62, signalling upside risk potential of 13.63%. On the other hand Biogen, Inc. has an analysts' consensus of $180.69 which suggests that it could grow by 3.37%. Given that Pfizer Inc. has higher upside potential than Biogen, Inc., analysts believe Pfizer Inc. is more attractive than Biogen, Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.83%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Biogen, Inc. quarterly revenues of $2.5B. Pfizer Inc.'s net income of $3.6B is higher than Biogen, Inc.'s net income of $466.5M. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.68x while Biogen, Inc.'s PE ratio is 15.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.29x versus 2.65x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of -19.69%. Pfizer Inc.'s return on equity of 10.84% beat Moderna, Inc.'s return on equity of -30.18%.

Pfizer Inc. has a consensus price target of $28.62, signalling upside risk potential of 13.63%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 8.73%. Given that Pfizer Inc. has higher upside potential than Moderna, Inc., analysts believe Pfizer Inc. is more attractive than Moderna, Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.83%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Moderna, Inc. quarterly revenues of $1B. Pfizer Inc.'s net income of $3.6B is higher than Moderna, Inc.'s net income of -$200M. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.68x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.29x versus 5.86x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of 38.89%. Pfizer Inc.'s return on equity of 10.84% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Pfizer Inc. has a consensus price target of $28.62, signalling upside risk potential of 13.63%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 2.86%. Given that Pfizer Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.83%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Pfizer Inc.'s net income of $3.6B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.68x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.29x versus 5.94x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of --. Pfizer Inc.'s return on equity of 10.84% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Pfizer Inc. has a consensus price target of $28.62, signalling upside risk potential of 13.63%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 165.39%. Given that Viking Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Pfizer Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.83%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Pfizer Inc.'s net income of $3.6B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.68x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.29x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.